thymosin alpha 1 lung cancer lung cancer - Thymosinfunction Thymosin α1 promotes the activation of myeloid-derived suppressor cells Thymosin Alpha 1 Lung Cancer: A Comprehensive Overview of its Therapeutic Potential

Thymosinfunction Thymosin alpha 1 (Tα1), a naturally occurring peptide hormone composed of 28 amino acids, has emerged as a significant area of research in the fight against lung cancer作者：RS Schulof·被引用次数：13—Thymosin Alpha 1Applications in Immunotherapy ... An Evaluation of Two Different Schedules of Synthetic Thymosin α1 Administration in Patients withLung Cancer.. Its established role as an immunostimulant and its capacity to inhibit tumor growth have led to its investigation, and in some cases, its approval for various cancer treatments. This article delves into the current understanding of thymosin alpha 1 lung cancer therapeutic applications, exploring its mechanisms of action, clinical efficacy, and potential for improving patient outcomes.Thymosin Alpha-1 - Regulations.gov

Recognized for its immunomodulatory properties, Tα1 is frequently administered to lung cancer patients to bolster their immune systems, thereby aiding in the prevention of infections and improving overall well-being作者：R Peng·2020·被引用次数：9—Thymosin alpha 1 (Tα1), a hormone that contains 28 amino acids,is already approved for cancer treatment. However, its clinical application is limited because .... Research has indicated that thymosin alpha 1 can significantly improve overall survival (OS) in patients with surgically resectable non-small cell lung cancer (NSCLC).2016年9月19日—Phase I/Phase II, multi-center, open label, randomized, parallel group study to determine the safety/tolerability/efficacy ofThymosin alpha 1in patients with sensitizing EGFR mutation positive NSCLC taking SoC versus SoC alone. The study will be conducted in subjects with sensitizing EGFR mutation ... Furthermore, studies have demonstrated that thymosin alpha 1 has been tested in patients with a variety of cancers, including lung cancer, liver cancer, and melanoma, with encouraging results. Its effectiveness in treating lung cancer has been well-documented, highlighting its potential as a valuable therapeutic agent.

The precise mechanisms by which thymosin alpha 1 exerts its anti-cancer effects are multifaceted. It is known to promote the activation of myeloid-derived suppressor cells in models of lung cancer by upregulating Arginase 1. Additionally, thymosin alpha 1 has been shown to inhibit cell proliferation and induce apoptosis (programmed cell death) in human non-small cell lung cancer cells both in vitro and in vivo. A notable study, "Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo," published in ACS Omega in 2020, demonstrated the compound's ability to suppress tumor growth. Moreover, research has shown that Tα1 can significantly decrease lung metastasis in experimental models.

The integration of thymosin alpha 1 into existing treatment regimens is a key area of focus. Studies suggest that Tα1 combined with chemotherapy drugs can exhibit a stronger anti-lung cancer and immunomodulatory effect than Tα1 alone, potentially due to a synergistic effect作者：RS Schulof·被引用次数：13—Thymosin Alpha 1Applications in Immunotherapy ... An Evaluation of Two Different Schedules of Synthetic Thymosin α1 Administration in Patients withLung Cancer.. This combination therapy approach is being explored to enhance treatment efficacy. For instance, the clinical efficacy and safety of synthetic thymic peptides, particularly thymosin alpha 1, when used concomitantly with chemotherapy, have been investigated, showing beneficial outcomes for patients作者：CL Guo·2021·被引用次数：22—A randomized trial to evaluate the immunorestorative properties of syntheticthymosin-alpha 1in patients withlung cancer. J Biol Response ....

Beyond its direct anti-tumor effects, thymosin alpha 1 plays a crucial role in immune restoration. A randomized trial in 1985 aimed to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer. More recent investigations, such as the work by CL Guo in 2021, found that Tα1 as adjuvant immunomodulatory therapy can significantly improve Disease-Free Survival (DFS) and OS in patients with NSCLC after R0 resection, except for specific patient populations. This suggests thymosin alpha 1 can act as a valuable supportive therapy.Thymosin alpha 1 has been tested in patients with a variety of cancers, including lung cancer, liver cancer, and melanoma, with encouraging results. In many ... Interestingly, elevated plasma thymosin-α1 levels have been observed in lung cancer patients, with levels being higher in those with another co-existing cancer, hinting at a complex interplay between the peptide and cancer development.作者：RS Schulof·1985·被引用次数：122—Randomized trial to evaluate the immunorestorative properties ofsynthetic thymosin-alpha 1 in patients with lung cancer. Journal Article ...

The development of modified versions of thymosin alpha 1 is also contributing to its therapeutic potential. Modified Thymosin Alpha 1, specifically designed for improved distribution and efficacy, has shown promise in inhibiting the growth of lung cancer in vivo. Several studies have focused on the formulation and administration of thymosin alpha 1, including investigations into the impact of different schedules of synthetic thymosin-alpha 1 administration in patients with lung cancer.

Areas of ongoing research include the investigation of thymosin alpha 1 in patients with specific genetic mutations, such as those with sensitizing EGFR mutations in NSCLC. Clinical trials are evaluating the safety, tolerability, and efficacy of thymosin alpha 1 in conjunction with standard of care (SoC) for such patients. Furthermore, the potential of thymosin as a chemopreventive agent in lung and breast cancer is being explored. One study even indicated that thymosin alpha 1 is able to cure Lewis lung carcinoma in mice when used in combination with interferon after cyclophosphamide treatment.作者：RS Schulof·被引用次数：13—Thymosin Alpha 1Applications in Immunotherapy ... An Evaluation of Two Different Schedules of Synthetic Thymosin α1 Administration in Patients withLung Cancer.

In conclusion, thymosin alpha 1 lung cancer research highlights a promising therapeutic avenueThymosin α1 suppresses migration and invasion of PD-L1 .... Its immunomodulatory, anti-proliferative, and immune-restorative properties make it a valuable agent in the fight against lung cancerLung Cancer Prevention - NCI. While thymosin is already approved for cancer treatment in some contexts, ongoing research into its synergistic effects with chemotherapy, its role in improving survival rates, and the development of modified formulations continues to expand our understanding of its potential to significantly impact patient outcomes in lung cancer. The exploration of thymosin alpha 1 underscores the importance of immune-adjuvant therapy in oncologyThymosin alpha 1: A comprehensive review of the literature - PMC - NIH.